This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Healthtech firm Harrison.ai of Sydney, Australia, has announced that it is expanding its operations into the U.S., a move supported and accelerated by $112 million in Series C funding. The funding round was led by Aware Super, ECP, and existing investors Horizons Ventures, Blackbird Ventures, and Alpha JWC Ventures. Australia's National Reconstruction Fund Corporation (NRFC), Ord Minnett, and Wollemi Capital Group participated as new investors.
In the next 30 years, the supply of radiologists is expected to grow by nearly 26%, assuming no increases in the number of new residents, experts wrote in JACR.
New research provides detailed insight into how specific factors that impact hormone levels, such as breastfeeding, contraception, medication and menopausal status, alter BPE on CEM.
Amidst rising cancer prevalence and soaring costs, new cancer technologies and innovations are emerging to support the early detection, treatment, and surveillance of cancer. Read this guide to understand how to evaluate these solutions for your employees and members – and to learn more about the current state of coverage, clinical and cost effectiveness, and impact on quality and outcomes.
Unless mitigating measures are taken, the current supply of radiologists in the U.S. and increased demand for imaging will likely lead to a continued workforce shortage, Harvey L. Neiman Health Policy Institute (HPI) researchers have warned. "Given the comparable projected levels of growth in supply and demand, the present radiologist shortage is projected to persist unless steps are taken to grow the workforce and/or decrease per-person imaging utilization," said lead author Eric Christensen, P
The controversy dates to February 2017 when a woman complaining of coughing underwent imaging, and a rad misinterpreted an abnormality as a "nipple shadow.
The controversy dates to February 2017 when a woman complaining of coughing underwent imaging, and a rad misinterpreted an abnormality as a "nipple shadow.
tim.hodson Wed, 02/12/2025 - 09:30 Feb. 11, 2025 Harrison.ai, a developer of AI-powered medical diagnostic support and workflow solutions, has announced the accelerated expansion of its operations into the United States a move supported by US$112 million of Series C funding. The funding will also fuel the companys product roadmap and continued growth in the UK, EMEA and APAC.
The Australian company offers Annalise Enterprise CXR, which leaders believe is the most comprehensive decision aid for X-ray reading, able to identify up to 124 findings.
February is National Cancer Prevention Month , a time to focus on the impact of early cancer detection and prevention. As healthcare providers, you know that catching cancer in its earliest stages significantly improves patient outcomes. Advanced imaging technologies continue to play a crucial role in detecting cancers before they progress, giving patients the best chance for successful treatment.
Ariceum Therapeutics has secured Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for actinium-225 (Ac-225) SSO110 for the treatment of small-cell lung cancer. The designation provides development and commercial incentives, including eligibility for seven years of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, and an exemption from FDA user fees, the company noted.
Patient-centric scheduling can only be achieved through optimized radiology workflows, effective communications between staff and physicians, and, of course, through specialized schedulers. In this guide, we’ll take you through a step-by-step process to transform your radiology center into a high-performance hub of medical imaging.
Cubresa has signed an agreement with Siemens Healthineers to integrate its BrainPET scanner into Siemens Magnetom MRI scanners. Cubresas BrainPET scanner is designed to expand the capabilities of MRI scanners by enabling brain-optimized simultaneous PET/MR imaging. The contract will initially focus on Siemens Magnetom Terra and Terra.X 7-tesla MRI scanners, with other field strengths and models to follow, Cubresa said.
Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
About 40% of us will be diagnosed with cancer in our lifetime, and patients are getting younger. At the same time, the cost of treatment continues to rise, with employers spending 8.5% more on cancer care for each employee than they did last year. The best thing employers can do for their employees and business tomorrow is to invest in cancer detection and care today.
A groundbreaking, minimally invasive treatment offers new hope for millions of people suffering from high blood pressure caused by primary aldosteronism.
A new imaging technology generates super-resolution images that reveal the inner structures of bones in greater detail, helping to better assess fracture risk.
The annual Editors Awards honor the most noteworthy research published in the Journal of Vascular and Interventional Radiology (JVIR). The winners of the Editors Award for Outstanding Clinical Study and the Editors Award for Outstanding Laboratory Investigation are chosen by a review of all manuscripts published in 2024, voted on by confidential ballot by the editorial board members, and finally selected by the Editor-in-Chief.
Discover how Color's comprehensive care solution is revolutionizing cancer screening adherence and knowledge. Through an in-depth case study, Color's unique approach to comprehensive cancer care has shown significant benefits in increasing screening rates and enhancing patient knowledge. Participants reported a 2-3x increase in adherence to screening guidelines over just 8 weeks, with 84% of participants increasing their familiarity with timing and frequency of cancer screening.
The Journal of Vascular and Interventional Radiology (JVIR) Editorial Board extends its thanks and appreciation to the following experts who provided manuscript reviews for the JVIR between January 1, 2024, and December 31, 2024. The constructive comments and sound judgments of knowledgeable and unbiased reviewers are fundamental to our blinded peer-review process.
Direct visualization of deep venous lesions with the ability to assess responses to treatment could present a major advance in venous interventions. A pilot in vivo feasibility study assessing use of a clinical endoscope for venous angioscopy was performed in a swine model. The angioscopy technique enabled visualization of the vein wall, of venous trauma and stenosis, and of response to stent placement.
Combined endobronchial ultrasound and endoscopic ultrasound (CUS) is a reliable tool for ruling out N2 disease in PET-negative lung cancer patients, researchers have reported. Researchers led by Baej Kuda, MD, from the Maria Skodowska-Curie National Institute of Oncology in Cracow, Poland found that while N2 disease prevalence in PET-negative mediastinal lymph nodes is low, CUS achieved a high negative predictive value (NPV) in assessing the presence of N2 disease.
Explore the latest insights from the American Cancer Society's “Cancer Statistics 2024” report, which unveils multiple alarming trends in cancer data. Cancer is on the rise among young adults, and diagnoses for 6 of the 10 most common cancers are escalating. With over 2 million new cancer cases projected in the U.S. this year, employers face increased challenges when it comes to supporting employees.
New research shows that premenopausal status, lactation, and hormone replacement therapy (HRT) all lead to higher background parenchymal enhancement grades on contrast-enhanced mammography.
A recent poll from Forbes Advisor shows that one in 10 workers would take a pay cut to access better employment benefits. While that’s not a staggering percentage, it does show that American workers think about more than their salaries. They also want benefits packages that help them lead more successful personal and professional lives. Employers, therefore, need to know how to negotiate beyond salary so they can attract top talent.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
130 
Let's personalize your content